格隆汇2月12日丨百奥泰(688177.SH)公布，公司于近日收到欧洲药品管理局（称"EMA"）签发的关于 Gotenfia®（BAT2506，戈利木单抗注射液）上市批准通知。适应症：类风湿关节炎，幼年特发性关节 炎，银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 戈利木单抗是靶向TNF-α的抗体，能够以高亲和力特异性地结合可溶性及跨膜的人TNF-α，阻断TNF-α 与其受体TNFR结合，从而抑制TNF-α的活性。Gotenfia®作为百奥泰又一个获得 EMA 上市批准的产 品，将进一步拓展公司国际化市场，提升公司产品的国际影响力，有望对公司长期经营业绩产生积极影 响。已上市竞品和其他潜在竞品可能会拥有先行者优势，Gotenfia®可能在未来面临激烈的市场竞争。 ...

经济观察网2026年2月4日，百奥泰公告与沙特制药企业Avalon Pharma签署协议，授予其BAT3306(帕博 利珠单抗)注射液在中东及北非地区的独家商业化权益。根据协议，百奥泰可获得最高700万美元款项， 包括200万美元首付款及基于销售额的分成，但药物研发和审批仍存不确定性。此外，2026年2月9日国 家集采药品接续采购开标，涉及抗肿瘤等领域，可能对医药行业整体带来稳定预期。 百奥泰2025年三季报显示，前三季度主营收入6.84亿元，同比增长17.57%；归母净利润亏损2.24亿元， 但同比收窄38.72%。单季度第三季度收入2.42亿元，同比增长34.92%，毛利率维持78.3%。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 近7日(2026年2月5日至11日)，百奥泰股价区间涨跌幅为2.71%，最高价24.65元(2月10日)，最低价23.35 元(2月5日)。2月10日收盘价24.26元，单日上涨0.96%，但主力资金净流出224.13万元；2月11日最新价 24.25元，主力资金继续净流出200.45万元。融资余额呈下降趋势，截至2月10日为1.94亿元，较前一日 减少1.07 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][33]. Core Insights - The pharmaceutical sector saw a slight increase of 0.14% in the week, while the Shanghai Composite Index decreased by 1.27% [3][2]. - The report highlights the implementation of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and other departments, aiming to enhance the supply chain and technological advancements in the traditional Chinese medicine sector [11][12]. - Key pharmaceutical products such as Eli Lilly's Tirzepatide are projected to generate significant sales, with estimates of $36.5 billion in 2025, reflecting a 99% year-on-year growth for the diabetes version and a 175% growth for the weight loss version [15][17]. - The report notes active licensing and collaboration in the industry, with significant deals such as a $1.5 billion agreement between Saint's RNAi therapy and Genentech, and various other collaborations involving companies like Jichuan Pharmaceutical and Baiyunguan [18][20]. Market Performance Summary - The overall valuation of the pharmaceutical sector is reported at 29.6 times earnings, ranking 13th among 31 sectors [4][14]. - The performance of various sub-sectors includes: - Raw materials (+0.6%) - Traditional Chinese Medicine (+2.6%) - Chemical preparations (-0.8%) - Medical devices (+0.1%) [4][3]. Key Events and Developments - The report emphasizes the importance of the new plan for traditional Chinese medicine, which includes goals such as establishing 60 high-standard raw material production bases and developing 10 major traditional Chinese medicine products by 2030 [12][11]. - Notable company developments include: - Eli Lilly's projected revenue growth driven by Tirzepatide [15]. - And the announcement of significant profit forecasts from Heptares Pharmaceuticals, indicating a shift towards profitability [16]. Investment Recommendations - The report suggests focusing on domestic companies related to traditional Chinese medicine, such as Zoli Pharmaceutical and Yunnan Baiyao, as well as innovative drug companies like Heng Rui Pharmaceutical and Bai Jie Shen Zhou [2][18].

Core Insights - Alibaba Cloud ranks first globally in the cloud service competitiveness growth index, maintaining its position as a leader for three consecutive years and being the only Chinese cloud provider in the leader quadrant [3] - Temu partners with Hungarian Post to enhance logistics for e-commerce businesses in Hungary, aiming to improve delivery efficiency for local consumers [4] - Pop Mart establishes its European headquarters in London, planning to open seven stores in the UK and create over 150 jobs [5] - Hesai Technology collaborates with Grab in Southeast Asia to distribute its LiDAR products, enhancing market supply capabilities [5] - Zhijidongli secures $200 million in Series B funding, focusing on R&D and global market expansion [9] - The global AI computing power construction is accelerating, with transformer factory orders in China extending to 2027 due to high demand [11] Alibaba Cloud - Alibaba Cloud is the only Chinese cloud vendor in the leader quadrant of the cloud service competitiveness growth index, serving over 300,000 Chinese enterprises going global [3] - Plans to establish new data centers in multiple countries including Japan, South Korea, and Brazil by 2026 to support Chinese enterprises' overseas development [3] - Collaborates with Transsion to implement advanced imaging technologies in Southeast Asia and Africa, significantly reducing processing time and costs [3] Temu and Logistics - Temu's partnership with Hungarian Post aims to improve logistics for local e-commerce sellers, allowing for streamlined package delivery and return management [4] - The collaboration will leverage Hungary's extensive postal network to enhance delivery services, especially in remote areas [4] Pop Mart - Pop Mart announces London as its European headquarters, with plans to open seven stores across the UK [5] - The move is expected to create over 150 jobs and solidify the brand's presence in the European market [5] Hesai Technology and Grab - Hesai Technology partners with Grab to become the exclusive distributor of its LiDAR products in Southeast Asia, enhancing market access [5] - This collaboration aims to meet the growing demand for high-quality LiDAR sensors across various industries [5] Zhijidongli - Zhijidongli completes a $200 million Series B financing round, with investments aimed at R&D and global market expansion [9] - The company focuses on human-robot interaction and plans to establish a localized ecosystem for technology integration in overseas markets [9] Global AI Computing Power - The demand for AI computing power is driving the global construction of computing infrastructure, with transformer orders in China extending to 2027 [11] - The U.S. market is experiencing longer delivery cycles for transformers, indicating a significant increase in demand for power supply solutions [11]

Key Insights - Temu and SHEIN have suspended their cross-border operations in Turkey, shifting towards localized operations due to regulatory changes [5] - Hungarian Post has signed a memorandum of understanding with Temu to enhance cross-border logistics cooperation [6] - TSMC's 2nm production capacity has been fully booked by major tech companies, indicating strong demand for advanced semiconductor technology [7] - Hesai Technology has partnered with Grab to accelerate the deployment of LiDAR technology in Southeast Asia [8] - Anta is set to open its first store in the United States, marking a significant step in its global expansion strategy [10][13] - Baiotai has signed a licensing agreement for its BAT3306 injection in the Middle East and North Africa, with a potential transaction value of up to $7 million [15] - Alibaba Cloud has been recognized as the global leader in cloud service adoption for Chinese enterprises going abroad [16][18] - OpenAI's first AI headset, Dime, has been revealed, although its initial capabilities may be scaled back due to supply chain challenges [20][22] - Tesla plans to increase investments in AI hardware and energy sectors in China, with a projected capital expenditure exceeding $20 billion by 2026 [24]

Group 1: Events and Forums - The "Dubai Business Forum - China" will take place in Shenzhen on May 14, 2026, focusing on economic collaboration and investment opportunities between China and Dubai [2] - A closed-door sharing session on Japanese robot market entry will be held in Shenzhen on March 12, organized by JETRO and 36Kr [3] Group 2: Company Developments - Alibaba Cloud ranks first globally in the comprehensive competitiveness growth index, serving over 300,000 Chinese enterprises going abroad [4] - Temu has signed a memorandum of understanding with Hungary Post to enhance logistics for Hungarian e-commerce businesses [5] - TikTok Shop Southeast Asia has released guidelines for the use of AI-generated content, emphasizing transparency and authenticity [6] - Pop Mart has chosen London as its European headquarters, planning to open seven stores in the UK [7] - Hesai Technology has partnered with Grab for exclusive distribution of its LiDAR products in Southeast Asia [7] - Baidu's autonomous driving platform, Loobot, served as the only fully autonomous vehicle fleet at the World Government Summit in Dubai [7] - Caocao Travel has launched its ride-hailing service in approximately 16,000 cities across 42 countries [8] - IM Motors plans to achieve full coverage in the Middle East market within the year [8] - Anta will open its first flagship store in the U.S. on February 13, 2023 [8] - Baotai has signed a licensing agreement with Avalon Pharma for the commercialization of BAT3306 in the Middle East and North Africa [9] Group 3: Investment and Financing - Zhijidong completed a $200 million Series B financing round, with investments from UAE-based Stone Venture and others [10] - WoFei ChangKong raised nearly 1 billion yuan to accelerate its commercial delivery of eVTOL aircraft [10] - Weidu Technology initiated a $100 million Series C financing round to expand its electric heavy truck deliveries in global markets [10] - Lanjing Technology secured several million yuan in A+ round financing to enhance its overseas market expansion [11] Group 4: Market Trends and Policies - The global AI computing power construction is accelerating, with transformer factory orders in China extending to 2027 [12] - China's service trade is projected to reach 80,823.1 billion yuan by 2025, with a year-on-year growth of 7.4% [12]

证券代码：688177 证券简称：百奥泰 公告编号：2026-009 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 94 | | --- | --- | | 普通股股东人数 | 94 | | 2、出席会议的股东所持有的表决权数量 | 69,659,097 | | 普通股股东所持有表决权数量 | 69,659,097 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 40.9993 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 40.9993 | 百奥泰生物制药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 6 日 （二） 股东会召开的地点：广州市国际生物岛螺旋二路 18 号百奥泰创新中心一 楼展厅 （四） ...

FANGDA PARTNERS http://www.fangdalaw.com 本法律意见书仅供公司为本次股东会之目的使用。未经本所事先书面同意， 本法律意见书不得向任何第三方提供，或被任何第三方所依赖，或用作任何其他 目的。本所律师同意将本法律意见书随本次股东会决议按有关规定予以公告。 中国广东省广州市天河区珠江新城 电子邮件 E-mail: email@fangdalaw.com 珠江东路 6 号广州周大福金融中心 66 楼 01-06 单元 电 话 Tel.: 86-20-3225 3888 邮政编码: 510623 传 真 Fax: 86-20-3225 3899 文 号 Ref.: Unit 01-06, 66F, Guangzhou CTF Finance Centre, No.6 Zhujiang East Road, Zhujiang New Town, Tianhe District, Guangzhou, Guangdong, P.R. China 510623 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2026 年第一次临时股东会的法律意见书 致：百奥泰生物制药股份 ...

证券代码：688177 证券简称：百奥泰 公告编号：2026-008 百奥泰生物制药股份有限公司 自愿披露关于与 Avalon Pharma 就 BAT3306（帕博 利珠单抗）注射液签署授权许可及生产、供货和商 业化协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 协议履行期限：协议自生效日期起生效，十五年届满（初始期限）。初始期 限届满后，将自动延长两年（续签期限）。除非任何一方在初始期限或续签期限 届满前至少六个月，向另一方书面发出终止通知。 对上市公司当期业绩的影响： 协议的签订预计将对未来业绩产生积极影响，有利于提升公司的盈利能力。 协议履行中的重大风险及重大不确定性： 详见本公告之"五、协议履行的风险分析"。 重要内容提示: 协议内容摘要： 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）与Avalon Pharma（注册名：Middle East Pharmaceutical Industries Company，以下简称 "Avalon"）签署授权许可及生产、供货和商业化协议，将公司的B ...

Group 1 - The core point of the article is that Baiotai (688177.SH) has signed a licensing and commercialization agreement with Avalon Pharma for its BAT3306 (pembrolizumab) injection in the Saudi and MENA markets, with potential total payments up to $7 million [1][2] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a percentage of net sales as revenue sharing [1] - BAT3306 is developed based on guidelines from NMPA, FDA, and EMA for biosimilars and is an immuno-oncology drug classified as a humanized monoclonal antibody [1] Group 2 - The purpose of the agreement is to quickly convert the company's R&D achievements into economic benefits through commercial cooperation and licensing [2] - The collaboration with Avalon is expected to integrate advantages in R&D, production quality control, technology enhancement, clinical application, and commercial promotion, creating favorable conditions for the company's future development [2] - The successful implementation of the agreement is anticipated to have a positive impact on the company's future operating performance [2]